Omega Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in two upcoming investor conferences.
Jefferies Healthcare Conference
Fireside Chat
Date: Thursday, June 8, 2023
Time: 8:30 a.m. ET
Goldman Sachs 44th Annual Global Healthcare Conference
Fireside Chat
Date: Wednesday, June 14, 2023
Time: 2:40 p.m. PT / 5:40 p.m. ET
Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at . Archived replays will be available on the same website for approximately 90 days.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit , or follow us on and .
Contact: Eva Stroynowski 617.949.4370
